Brief: Alligator Bioscience Signs LoI With Unicancer For Phase 3 Mitazalimab Development
10/04/2026 13:54
April 10 (Reuters) - Alligator Bioscience AB ATORX.ST: SIGNS LETTER-OF-INTENT WITH UNICANCER FOR PHASE 3 MITAZALIMAB DEVELOPMENT AND UNICANCER TO PREPARE GLOBAL INVESTIGATOR SPONSORED PHASE 3 STUDY Source text: ID:nMFN1g4YT2 Further company coverage: ATORX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Alligator Bioscience AB
See all newsBrief: Alligator Bioscience Q1 Net Loss SEK 1.4 Million
Sweden's Alligator Bioscience posts Q1 net profit, narrows operating loss
Brief: Alligator Bioscience Q1 EBIT SEK -17.8 Million
Brief: Alligator Bioscience Signs LoI With Unicancer For Phase 3 Mitazalimab Development
Brief: Exercise Of Warrants Brings Alligator Bioscience Net Proceeds Of SEK 12 Mln